| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.037 | 0.8 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.8 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.8 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.8 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.8 |